NVAX
NOVAVAX INC
NASDAQ · Healthcare · Biotechnology · US
$10.11
+1.10%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.37
- Revenue estimate
- $72.7M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.32
- EPS estimate
- -$0.38
- Revenue actual
- $56.7M
- Revenue estimate
- $52.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +111.8%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.38 | -$0.32 | Beat 15.75% | $56.7M |
| May 6, 2026 | -$0.25 | -$0.06 | Beat 76.00% | $139.5M |
| Nov 6, 2025 | -$1.08 | -$0.62 | Beat 42.59% | $70.4M |
| May 8, 2025 | $0.71 | $2.93 | Beat 312.68% | $666.7M |
| Feb 27, 2025 | -$0.75 | -$0.51 | Beat 32.00% | $88.3M |
| Aug 8, 2024 | $1.64 | $0.99 | Miss -39.63% | $415.5M |
| May 10, 2024 | -$1.04 | -$1.05 | Miss -0.96% | $93.9M |
| Feb 28, 2024 | -$0.49 | -$1.44 | Miss -193.88% | $291.3M |
| Nov 9, 2023 | -$1.82 | -$1.26 | Beat 30.77% | $22.1M |
| Feb 28, 2023 | -$0.92 | -$2.28 | Miss -147.83% | $287.8M |
| Feb 28, 2022 | -$1.43 | -$11 | Miss -681.82% | $222.2M |
| Nov 4, 2021 | -$4.04 | -$4.31 | Miss -6.68% | $178.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026